Skip to main content

Bruce Alan Sullenger, PhD

Joseph W. and Dorothy W. Beard Professor of Experimental Surgery, in the School of Medicine
Professor of Surgery
Associate Professor in Molecular Genetics and Microbiology
Professor of Pharmacology and Cancer Biology
Professor of Neurosurgery
Office: 1079 MSRB II, Box 103035, Durham, NC 27710
Campus Mail: DUMC Box 103035, Durham, NC 27710

The main focus of my translational research laboratory is to develop RNA based therapeutic agents for the potential treatment of a range of diseases. To this end, we have and will continue to take advantage of the fact that RNA is not just a passive carrier of genetic instructions inside of cells during the conversion of information from DNA to RNA to protein. Rather, RNA is an extremely versatile biological macromolecule. Certian RNAs can bind to specific protiens with high affinities, while others can for catalytic centers and perform enzymatic reactions. These facets of RNA coupled with the ease with which RNA can be manipulated in vitro make it a very powerful and unique therapeutic agent whose potential is largely untapped. Durring our endeavors, we plan to work closely with the members of the Molecular Therapeutics program as well as other faculty at the Duke University Medical Center to expedite the development and testing of these therapeutics.

The specific aims of my laboratory are:

1. To isolate and characterize RNA and DNA aptamers which block therapeutically relavent proteins such as those involved in cardiovascular diseases and immune modulation.

2. To develop RNA-based tumor targeting strategies for delivering siRNAs and miRNAs to tumor cells.

3. To reprogram cells using mRNA delivery.

4. To explore novel methods to control inflammation.

Education and Training

  • Ph.D., Cornell University, 1990

Selected Grants

Weight: 
-20

Publications

Buddai, Sai K., Juliana M. Layzer, Genmin Lu, Christopher P. Rusconi, Bruce A. Sullenger, Dougald M. Monroe, and Sriram Krishnaswamy. “An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase..” J Biol Chem 285, no. 8 (February 19, 2010): 5212–23. https://doi.org/10.1074/jbc.M109.049833.

Full Text

Mi, Jing, Yingmiao Liu, Zahid N. Rabbani, Zhongguang Yang, Johannes H. Urban, Bruce A. Sullenger, and Bryan M. Clary. “In vivo selection of tumor-targeting RNA motifs..” Nat Chem Biol 6, no. 1 (January 2010): 22–24. https://doi.org/10.1038/nchembio.277.

Full Text

Wang, Jialiang, Timothy P. Wakeman, Justin D. Lathia, Anita B. Hjelmeland, Xiao-Fan Wang, Rebekah R. White, Jeremy N. Rich, and Bruce A. Sullenger. “Notch promotes radioresistance of glioma stem cells..” Stem Cells 28, no. 1 (January 2010): 17–28. https://doi.org/10.1002/stem.261.

Full Text

Nimjee, Shahid M., Sabah Oney, Zoya Volovyk, Kristin M. Bompiani, Steve B. Long, Maureane Hoffman, and Bruce A. Sullenger. “Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin..” Rna 15, no. 12 (December 2009): 2105–11. https://doi.org/10.1261/rna.1240109.

Full Text

Fortenberry, Yolanda, Charlene M. Blake, and Bruce A. Sullenger. “Effect of PAI-1 Specific RNA Aptamers On Cell Adhesion and Motility.” In Blood, 114:840–840. AMER SOC HEMATOLOGY, 2009.

Scholars@Duke

Oney, Sabah, Ruby T. S. Lam, Kristin M. Bompiani, Charlene M. Blake, George Quick, Jeremy D. Heidel, Joanna Yi-Ching Liu, et al. “Development of universal antidotes to control aptamer activity..” Nat Med 15, no. 10 (October 2009): 1224–28. https://doi.org/10.1038/nm.1990.

Full Text

Zhou, Jing, Boonchoy Soontornworajit, Jacob Martin, Bruce A. Sullenger, Eli Gilboa, and Yong Wang. “A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling..” Macromol Biosci 9, no. 9 (September 9, 2009): 831–35. https://doi.org/10.1002/mabi.200900046.

Full Text

Blake, Charlene M., Bruce A. Sullenger, Daniel A. Lawrence, and Yolanda M. Fortenberry. “Antimetastatic potential of PAI-1-specific RNA aptamers..” Oligonucleotides 19, no. 2 (June 2009): 117–28. https://doi.org/10.1089/oli.2008.0177.

Full Text

Pages